Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 has been demonstrated to confer a prognostic value in colorectal cancer (CRC), but no studies have investigated whether this association differs according to tumour location. In this study, immunohistochemical expression of PD-1 and PD-L1 was analysed in tissue microarrays with primary tumours from 557 incident CRC cases from a prospective population-based cohort. Univariable and multivariable Cox regression analyses, adjusted for age, sex, TNM stage, differentiation grade and vascular invasion, were applied to determine the impact of biomarker expression on 5-year overall survival (OS), in the entire cohort and in subgroup analysis of right colon, left colon, and rectum. High PD-L1 expression on tumour-infiltrating immune cells was an independent factor of a prolonged OS in the entire cohort (hazard ratio [HR] D 0.49; 95% confidence interval [CI] CI 0.35 -0.68), and in tumours of the right colon (HR D 0.43; 95% CI 0.25 -0.74) and the left colon (HR D 0.28; 95% CI 0.13 -0.61), but not in rectal cancer. Tumour-specific PD-L1-expression was not prognostic, neither in the full cohort nor according to tumour location. High immune cell-specific PD-1 expression was associated with a prolonged OS in the entire cohort and in tumours of the right colon, but not in the left colon or rectum, and only in univariable analysis. In conclusion, these results demonstrate that immune cell-specific PD-L1 and PD-1 expression is prognostic in a site-dependent manner, whereas tumour-specific PD-L1-expression is not prognostic in CRC.
Introduction
Colorectal cancer (CRC) is the second most common cancer in women and the third most common cancer in men worldwide. Despite advances in treatment, CRC is still the third most frequent cause of cancer-related death. 1 Programmed cell death protein 1 (PD-1) is expressed by both lymphoid 2 and non-lymphoid immune cells, 3, 4 and is up-regulated upon after engagement of T cell or B cell receptors on na€ ıve lymphocytes. 2, 4 Activation of PD-1 by its ligand PD-L1 induces down-regulation of lymphocyte proliferation and cytokine production, resulting in lymphocyte deletion. 5 Indeed, expression of PD-L1 on tumour cells has been found to suppress CD8 C T cell activity and to be associated with an impaired prognosis is several types of solid cancer. [6] [7] [8] Immunotherapy has emerged as a promising approach for cancer treatment, 9, 10 and checkpoint inhibitors, targeting PD-1 or PD-L1, have demonstrated objective response in several types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others. 11 In CRC, the clinical benefit of PD-1 or PD-L1 blockade remains uncertain, however, a few studies report a positive effect of anti-PD-1 antibodies in patients with microsatellite instability (MSI) high tumours 12, 13 and anti-PD-1 therapies were recently approved by the U.S Food and Drug Administration for treatment of any type of advanced MSI-high cancer.
Despite increasing evidence reporting multiple differences in epidemiology, clinicopathological features, prognosis, and treatment response between proximal and distal CRC, no studies have hitherto evaluated the prognostic impact of PD-1 and PD-L1 expression in relation to primary tumour location (PTL). The aim of this study was therefore to investigate the prognostic impact of immune cell-specific PD-1 and PD-L1 expression, respectively, and tumour-specific PD-L1 expression, in tumours from incident CRC cases in a large, prospective, population-based Swedish cohort, with particular emphasis on the anatomical location of the primary tumour. In light of previous findings regarding tumour-infiltrating T cells and B cells in the herein investigated cohort, 14 we hypothesized that the prognostic impact of PD-1 and PD-L1 expression would be of furthermost importance in tumours of the right colon, rather than in tumours of the left colon or the rectum.
Results
Distribution of immune cell-specific PD-1 and PD-L1 expression and tumour cell-specific PD-L1 expression according to primary tumour site Information on tumour location was available for 555/557 (99.6%) cases in the tissue microarray (TMA), with 201 (36.1%) right-sided colon tumours, 145 (26.0%) left-sided colon tumours, and 209 (37.5%) rectal tumours.
PD-1 expression could be determined in 526 (94.4%) cases, whereby 228 (43.3%) cases were found to have low expression and 298 (56.7%) cases to have high expression of PD-1. Immune cell-specific PD-L1 expression could be evaluated in 536 (96.2%) cases, with 239 (44.6%) cases demonstrating low PD-L1 expression, and 297 (55.4%) cases demonstrating high PD-L1 expression. Tumour cell-specific PD-L1 expression was assessable in 536 (96.2%) cases, with 429 (68.5%) cases displaying negative (0-1%) expression, 52 (8.3%) positive expression in 1-4%, 17 (2.7%) positive expression in 5-9%, 13 (2.1%) positive expression in 10-49%, and 25 (4.0%) cases displaying positive expression in 50-100% of tumour cells. Sample immunohistochemical (IHC) images are shown in Fig. 1 .
Stainings were also evaluated on whole tissue sections and compared with the results from the TMA-based analysis. As demonstrated in Supplementary Table S1, 5/15 cases had a discrepant score in the whole section regarding immune cell-specific PD-1 expression, not differing more than one category, and in 2/15 cases, the difference also affected the dichotomized categories. As shown in Supplementary Table S2, 6/25 cases had a discrepant score in the whole section regarding immune cell-specific PD-L1 expression, not differing more than one category, and in 1/25 cases, the difference also affected the dichotomized categories. Regarding tumour cell-specific PD-L1 expression, a discrepant score was observed in 9/25 cases, differing more than one category in 2/25 cases (Supplementary  Table S2 ).
PD-1 and PD-L1 expression was also compared in cases of rectal cancer in patients who did and did not receive neoadjuvant therapy. There was no significant difference in the expression of PD-L1 in immune cells or tumour cells, whereas the density of PD-1 C immune cells was significantly lower in tumours from cases having received neoadjuvant treatment (Supplementary Table S3) .
Associations of immune cell-specific PD-1 and PD-L1 expression and tumour cell-specific PD-L1 expression with clinicopathological factors, according to primary tumour site For correlation analyses between immune cell-specific PD-1 and PD-L1 expression and clinicopathological factors, cases were divided into groups of low (0-9%) and high (10-100%) PD-1 C and PD-L1 C immune cells, and tumour-cell specific PD-L1 expression was divided into three groups of low (< 1%) and high (1-100%) positive tumour cells. Associations between PD-1 and PD-L1 expression and established clinicopathological characteristics and other investigative biomarkers in relation to PTL are demonstrated in Tables 1, 2, and 3. PD-1 expression was significantly associated with lower Tstage (p D 0.015 for the right colon and p < 0.001 for the rectum) and with lower M-stage (p D 0.001) in right-sided colon cancers (Table 1) . Immune cell-specific PD-L1 expression was significantly associated with lower T-stage in each tumour location (p D 0.017 for the right colon, p D 0.008 for the left colon, and p < 0.001 for the rectum), and with lower N-stage (p D 0.002) and M-stage (p D 0.011) in right-sided colon cancers (Table 2) . Tumour cell-specific PD-L1 expression was significantly associated with lower age (p D 0.034) and with high differentiation grade (p D 0.040) in patients with right-sided colon cancers (Table 3) .
Neither PD-1 nor PD-L1 expression in immune cells was associated with BRAF or KRAS mutation status.
PD-1 and PD-L1 expression in immune cells was significantly higher in MSI tumours than in microsatellite stable (MSS) tumours, but only in right-sided tumours (p < 0.001, and p D 0.001, respectively; Tables 1,2) , and PD-L1 expression in tumour cells was significantly higher in MSI tumours in both right-sided colon cancers and rectal caners (p < 0.001 and p D 0.006, respectively; Table 3 ).
PD-1 expression was significantly associated with immune cell-specific PD-L1 expression, in the entire cohort (p < 0.001) as well as in each tumour subsite (p < 0.001 for all). Furthermore, PD-1 expression correlated with tumour cell-specific PD-L1 expression, in the entire cohort (p < 0.001) and in right-sided and left-sided colon cancers (p < 0.001 and p < 0.001, respectively). Finally, immune cell-specific PD-L1 was associated with tumour cell-specific PD-L1 expression, in the entire cohort (p < 0.001) and in each tumour location (p < 0.001 for all). 
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Associations of immune cell-specific PD-1 and PD-L1 expression and tumour cell-specific PD-L1 expression with T lymphocyte and B lymphocyte density
Since the prognostic value of B lymphocytes, plasma cells and various subsets of T lymphocytes has previously been shown do differ according to PTL in the herein investigated cohort, 14, 15 their associations with PD-1 and PD-L1 expression were also examined. There were significant correlations between PD-1 expression and T and B cell infiltration, being most evident in right-sided tumours (Table 1) . Immune cellspecific PD-L1 expression also correlated significantly with dense infiltration of T cells and B cells, in the entire cohort as well as in right-sided and left-sided colon cancers, and in rectal cancers (Table 2) . Finally, tumour cell-specific PD-L1 expression was significantly associated with T cell and B cell infiltration in right-sided and left-sided colon cancers (Table 3) .
Prognostic significance of immune cell-specific PD-1 and PD-L1 expression and tumour cell-specific PD-L1 expression according to primary tumour site Kaplan-Meier analysis according to all annotated categories demonstrated that PD-1 expression in immune cells was not significantly associated with survival ( Fig. 2A-C) , whereas intermediate or high expression of PD-L1 in immune cells was significantly associated with an improved 5-year overall survival (OS) in tumours of the right colon (Fig. 2D ) and in the left colon (Fig. 2E ), but not in the rectum (Fig. 2F) . Tumourspecific PD-L1 expression was not prognostic in any tumour location (Fig. 2G-I ).
In the entire cohort, the prognostic value of PD-1 expression in immune cells was only significant for low vs negative expression ( Supplementary Fig. 1A) , whereas intermediate or high PD-L1 expression in immune cells was significantly associated with an improved 5-year OS ( Supplementary Fig. 1B) , and tumour-specific PD-L1 expression was not prognostic in any tumour location (Supplementary Fig. 1C ).
For further survival analyses of immune cell-specific PD-1 and PD-L1 expression, cases were divided into groups of low (0-9% positive cells; n D 239, n D 228, and n D 498, respectively) and high (10-100% positive cells; n D 297, n D 298, and n D 38, respectively) expression.
Cox proportional hazards analyses of 5-year OS according to expression of PD-1 and PD-L1 in immune cells and PD-L1 expression in tumour cells, respectively, in relation to tumour subsite are shown in Table 4 . The time-dependent covariate was non-significant for immune cell-specific PD-1 and PD-L1 expression as well as for tumour cell-specific PD-L1 expression, and therefore, the factor x time interaction term was dropped from the model. The proportional hazard assumption was also considered to be satisfied with graphical evaluation using logminus-log plots (data not shown). Univariable hazard ratios for factors included in the multivariable analysis are shown in Supplementary Table S4 .
In univariable Cox regression analysis, high PD-1 expression was confirmed to be associated with an improved 5-year OS in the entire cohort (hazard ratio [HR] D 0.69; 95% confidence interval [CI] 0.52 -0.91) and in tumours of the right colon (HR D 0.57; 95% CI 0.36 -0.89), however, these associations did not remain significant in multivariable analysis, after adjustment for age, sex, TNM stage, differentiation grade, and vascular infiltration ( Table 4) Cox regression analyses for immune cell-specific PD-1 and PD-L1 expression, respectively, after exclusion of rectal cancer cases having received neoadjuvant therapy are shown in Supplementary Table S5 . In the entire cohort, immune cell-specific PD-L1 expression remained an independent prognostic factor and PD-1 expression was prognostic in univariable but not in multivariable analysis.
Tumour-specific PD-L1 expression was not prognostic for any of the tested cut-offs at 1%, 5%, or 10%, neither in univariable nor in multivariable Cox regression analysis, (Supplementary Table S6 ).
There was a significant interaction between high PD-L1 expression in immune cells and tumour location in the right and left colon vs. the rectum (p for interaction D 0.019). No significant interactions were observed between PD-1 expression in immune cells or PD-L1 expression in tumour cells and any tumour location.
Survival analysis in strata according to adjuvant chemotherapy in curatively treated stage III patients revealed no prognostic significance of neither immune cell-specific PD-1 or PD-L1 expression nor tumour cell-specific PD-L1 expression (data not shown).
Discussion
Although several studies have investigated the prognostic impact of PD-1 and PD-L1 expression in CRC, [16] [17] [18] [19] [20] [21] this study is, to the best of our knowledge, the first to investigate whether this association differs by the anatomical location of the primary tumour.
In the entire cohort, high expression of PD-L1 in tumourinfiltrating immune cells was found to be independently associated with an improved prognosis, which is in line with previous findings in CRC. 17, 19, 22 Moreover, in subsite analysis according to PTL, PD-L1 expression was independently associated with a prolonged survival in patients with rightsided and left-sided colon cancers, but not in patients with rectal cancer. These findings further support previous evidence suggesting that proximal and distal CRC may represent different epidemiological, pathological, genetic, and clinical entities. 23, 24 Right-sided tumours, often defined as proximal to the splenic flexure, are generally poorly differentiated, diagnosed in more advanced tumour stages, displaying different molecular patterns, and carrying a poorer prognosis than left-sided tumours. 24, 25 Several studies also demonstrate the importance of taking PTL into account when evaluating treatment response, [26] [27] [28] and retrospective analyses from large phase III trials have demonstrated that patients with right-sided tumours have less benefit from the addition of EGFR-targeted therapy.
29 Figure 2 . Kaplan-Meier estimates of overall survival according to immune cell-specific PD-1 and PDL-1 expression and tumour cell-specific PD-L1 expression, and primary tumour location. Kaplan-Meier analysis of 5-year overall survival in strata of 0-9 %, 10-49 %, and 50-100 % immune cells positive for PD-1 (A, B, C) and PD-L1 (D, E, F) staining, and <1 %, 1-4 %, 5-9 %, 10-49 %, and 50-100 % tumour cells positive for PD-L1 staining (G, H, I), in right-sided (first row) and left-sided (second row) colon cancers, and rectal cancer (third row). Table 4 . Cox proportional hazards models for 5-year overall survival in relation to immune cell-specific PD-1 and PD-L1 expression, and tumour cell-specific PD-L1 expression High PD-L1 expression in immune cells correlated significantly with dense CD8 C T cell infiltration, which in the herein investigated cohort has been found to be an independent prognostic factor.
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14 This may indicate a general activation of the immune response. Nevertheless, the prognostic impact of PD-L1 was independent of CD8 C T cell infiltration, suggesting that PD-L1 expression itself carries a prognostic value. Another explanation to the favourable impact of PD-L1 expression, contradicting results from other types of solid cancer, is that the immune cell infiltration in CRC might be associated with paradoxical features due to the microbiota of the colon. For example, in contrast with the majority of human cancers, the infiltration of FoxP3 C immune cells in CRC has in the herein investigated cohort 14 and others, 30, 31 been found to be an auspicious prognostic factor. It should however be pointed out that the herein described inter-correlations between different subsets of immune cells merely reflect their co-localization in selected tumour regions. Moreover, although there was a good agreement between PD-1 and PD-L1 expression in the TMA cores and whole tissue sections, the latter may not be sufficient for comprehensive mapping of tumour-infiltrating immune cells. Rather, applying the TMA technique for multiple sampling of cores from different tumour blocks, representing both the tumour and adjacent stroma, would likely provide more accurate information.
Whereas immune cell-specific PD-L1 expression was found to be an independent prognostic factor, tumour cell-specific PD-L1 expression was not associated with survival neither in the full cohort nor in subgroup analysis according to PTL, supporting previous reports in CRC 16, 17, 19, 22 and other cancers. [32] [33] [34] Nonetheless, an abundance of studies have reported high PD-L1 expression to be associated with an impaired prognosis due to induction of immune evasion, 6, 7, 35 being the rationale for PD-1/ PD-L1 blockade. 36, 37 Noteworthy, a significant part of studies regarding the prognostic impact of PD-L1 have not discriminated between its expression in tumour cells and tumour-infiltrating immune cells. The results from the present study, with immune cell-specific PD-L1 expression being an independent prognostic factor while its expression in tumour cells was not, are coherent with previous research 16, [23] [24] [25] [26] and demonstrate that PD-L1 expression in immune cells and tumour cells might carry different prognostic values and might be regulated by distinct mechanisms. Furthermore, although tumour cell-specific PD-L1 expression has been validated as a predictive marker for response to PD-1 or PD-L1 blockade in several cancers, 11, 38, 39 recent studies now suggest that PD-L1 expression in tumour-infiltrating myeloid and T cells also play a critical role in immunosuppression, 38, [40] [41] [42] [43] and should possibly be taken into account in assessment scoring for PD-1/PD-L1 blockade.
Although the favourable impact of PD-L1 expression in tumour-infiltrating immune cells was independent of MSI status in the entire cohort as well as in right-sided tumours, the prognostic impact was only evident in MSS tumours. In contrast, previous studies concerning treatment response from PD-1 or PD-L1 blockade in CRC report clinical benefit only for patients with MSI-high tumours, 12, 13 possibly explained by the fact that MSI-high tumours generally carry a higher mutational load, resulting in a robust T cell response which can be exploited by relieving the negative pressure. Nevertheless, Droeser et al. found that strong PD-L1 expression in CRC cells correlated with improved survival only in patients with MSS tumours, and that high PD-L1 was associated with an increased CD8 C T cell infiltration. 18 They hypothesized that the favourable impact of PD-L1 in MSS tumours might be coupled with the concomitant dense cytotoxic T cell infiltration. This may also explain the results from the present study, as there was a significant correlation between a high density of CD8 C T cells and high PD-L1 expression in MSS tumours.
Immune cell-specific PD-L1 expression was significantly higher in tumours with lower TNM stage, both in the entire cohort and in right-sided tumours. Furthermore, PD-L1 expression in both immune cells and tumour cells was significantly associated with MSI tumours, which is in line with previous research. 44 These data further support an auspicious prognostic impact of immune cell-specific PD-L1 expression. Consistent with previous research, 45 high PD-L1 expression in tumour cells correlated significantly with older age and female sex. Furthermore, tumour cell-specific expression of PD-L1 was significantly associated with immune cell-specific PD-1 and PD-Ll expression, supporting results from other studies. 39 Of note, the majority of previous studies regarding PD-1 and PD-L1 expression in cancer have focused on the predictive value for PD-1/PD-L1 blockade, with the choice of antibody and scoring algorithm depending on the selected PD-1/PD-L1-pathway inhibitor. The aim of this study was to examine the prognostic value of PD-1 and PD-L1 expression in CRC, with particular reference to PTL. Studies regarding the prognostic impact of PD-1 and PD-L1 expression have used different categorical cut-offs, [16] [17] [18] [19] [20] [21] some also including staining intensity, and no consensus has yet been reached regarding an optimal prognostic cut-off. For evaluation of tumour cell-specific PD-L1 expression, we applied cut-offs commonly used in clinical studies 46 and the prognostic value of PD-1 C immune cells was validated using the total count. The results from the present study, demonstrating that immune cell-specific PD-1 and PD-L1 expression carries the most evident prognostic value in rightsided CRC, are not likely to be disputed by alternative scoring systems.
In the present study, no independent associations between PD-1 expression and prognosis were found, neither in the full cohort, nor in subsite analysis. This is in contrast with a previous study on CRC, where Li et al. demonstrated PD-1 to be an independent prognostic factor for both OS and disease-free survival in patients with MSS tumours. 17 Moreover, PD-1 expression has been demonstrated to carry an independent favourable impact in gastric, 47 ovarian, 48 and head and neck cancer, 49 among others. Further studies are warranted to elucidate the prognostic impact of PD-1 expression in CRC, particularly regarding PTL.
Of note, a significant part of studies on CRC regarding PTL exclude the transverse colon altogether, and a rather large proportion of these studies also include rectal cancers into leftsided CRC. However, rectal cancer differs from descending and sigmoid colon cancer in molecular features, treatment approaches, and prognosis. 50, 51 Thus, we believe that it is more appropriate to apply the herein used definition on future studies.
Nonetheless, there are some limitations to the study. First, although the study cohort is derived from a large, prospective population-based cohort with clinically and histopathologically well-characterised CRC cases, there is a potential risk of selection bias as the study was made retrospectively. Furthermore, previous studies have used different antibodies and various cutoffs to define high and low expression of PD-L1 and PD-1, respectively, making it problematic to compare the results. Finally, several factors have been reported to affect the expression of PD-1 and PD-L1, including chemotherapy 52,53 and radiotherapy. 22 However, in the present cohort, only 61 (29,8%) of patients with rectal cancer received neoadjuvant treatment, and we found similar results regarding the prognostic value of the investigated biomarkers when excluding neoadjuvant treated rectal cancer patients. Moreover, while the density of PD-1 C immune cells was significantly lower in tumours from rectal cancer patients having received neoadjuvant treatment, the density of PD-L1
C immune cells and the distribution of tumour cell-specific PD-L1 expression did not differ between treated and untreated cases. However, we did not compare the expression of PD-1 and PD-L1 in pre-treatment biopsies and post-treatment surgical specimens, which would indeed be of relevance in future studies.
Conclusion
This study is, to the best of our knowledge, the first to demonstrate that the prognostic impact of PD-L1 and PD-1 expression differs according to primary tumour site in CRC. Dense infiltration of PD-L1 C immune cells was an independent prognostic factor in right-sided and left-sided colon cancer, but not in rectal cancer. These results need validation, but may be clinically relevant, as they indicate that tumour location might be an important factor to take into consideration in therapeutic decisions, including eligibility for immunotherapy.
Patients and methods

Patients
The study cohort consists of all incident cases of CRC in the Malm€ o Diet and Cancer Study from 1991 up until December 31st 2008 (n D 626), from which 557 cases were available for TMA construction. 14, 15, 54, 55 The Malm€ o Diet and Cancer Study is a prospective population-based cohort with the primary aim to investigate associations between various dietary factors and cancer incidence. 56 The project, including non-participants in the European Prospective Investigation into Cancer (EPIC) cohort, enrolled 18326 women (60.2%) and 12120 (39.8%) men, with a total of 30446 participants (from a background population of 74,138).
Information on CRC incidence was obtained through the Swedish Cancer Registry up until 31 December 2007, and from The Southern Swedish Regional Tumour Registry for the period of 1 January -31 December 2008. Clinical and treatment data were obtained from medical charts. Histopathological data were obtained from pathology records. TNM staging was performed according to the American Joint Committee on Cancer. Right colon was defined as appendix, caecum, ascending and 2/3 of transverse colon, whereas left colon was defined as the left colic flexure, descending and sigmoid colon, corresponding to the midgut fetal origin versus the hindgut as well as different innervation and blood supply.
Median 57 and KRAS and BRAF mutation status was determined by pyrosequencing as previously described. 58 All EU and national regulations and requirements for handling human samples have been fully complied with during the conduct of this project; i.e. decision no. 1110/94/EC of the European Parliament and of the Council (OJL126 18,5,94), the Helsinki Declaration on ethical principles for medical research involving human subjects, and the EU Council Convention on human rights and Biomedicine. The study was approved of by the Ethics committee of Lund University (ref nr 51/90, 445/07 and 530/08). Written informed consent has been obtained from each subject.
Tissue microarray construction
All tumours with available slides or paraffin blocks were histopathologically re-evaluated on haematoxylin and eosin stained slides by a senior pathologist (KJ). Cases with an insufficient amount of tumour material were excluded, whereby a total number of 557 (89.0%) cases were available for TMA construction. Representative and non-necrotic areas were marked, and TMAs were constructed with duplicate tissue cores (1 mm) taken from each primary tumour and mounted in a recipient block, using a semi-automated arraying device (TMArrayer, Pathology Devices, Westminister, MD, USA). Four mm sections from this block were subsequently cut using a microtome and mounted on glass slides.
Immunohistochemistry
For IHC analysis of PD-L1, 4 mm TMA-sections were pretreated with Flex TRS High, pH 9, and subsequently stained in an Autostainer Plus (Dako; Glostrup, Denmark) with the anti-PD-L1 antibody (clone E1L3N, rabbit, dilution 1:200, Cell Signalling Technologies, Danvers, MA 01923, USA). For analysis of PD-1, TMA-sections were pre-treated using Flex TRS Low, pH 6,1, and stained with the anti-PD-1-antibody (ab52587, clone NAT105, mouse, dilution 1:50, AbCam; Cambridge, UK). Endothelial cells and normal colonic mucosa were used as negative internal controls. The density of B cells (CD20 C , FoxP3 C ) was analysed as previously described.
14,15
Evaluation of PD-1 and PD-L1 expression
Immune cell-specific PD-L1 and PD-1 expression was annotated as the estimated percentage of stained cells and categorized as 0-9%, 10-49% and 50-100% stained immune cells. PD-L1 expression on tumour cells was annotated as the estimated percentage of stained cells and categorized as < 1%, 1-4%, 5-9%, 10-49%, and 50-100% stained tumour cells. Cells with linear membranous staining were counted as positive. Staining intensity was not accounted for, as only minor variations were observed. For PD-1 expression, the total number of positive immune cells was also counted. The annotated score in the TMA was also compared with whole tissue sections by blinded analysis of 15 cases with 5 representing each category of PD-1 expression in immune cells, and 25 cases with 5 cases representing each category of PD-L1 expression in tumour cells and 7, 7, and 11 cases, respectively, of categories 0, 1, and 2 for PD-L1 C immune cells. All stainings were evaluated independently by two observers (KJ and JB) blinded to clinical outcome, one being a board-certified pathologist (KJ). Discrepant cases were re-evaluated and discussed in order to reach consensus.
Statistical analysis
Chi-square tests and Mann Whitney U tests were used to evaluate associations between categories of PD-1 and PD-L1 expression and established clinicopathological characteristics and other investigative biomarkers. Kaplan-Meier analysis and log rank test were applied to illustrate differences in five-year OS with respect to categories of PD-1 and PD-L1 expression. CRT analysis was applied to determine the optimal prognostic cut-off for PD-1 C immune cell count. Cox regression proportional hazard models were used to estimate hazard ratios for death within 5 years in both univariable and multivariable analysis, adjusted for age, sex, Tstage, N-stage, M-stage, differentiation grade, and vascular invasion.
The proportional hazard assumption was tested using Cox regression with a time-dependent covariate analysis, whereby the proportional hazard assumption was considered to be satisfied when the factor x time interaction was non-significant.
To estimate the interaction effect between tumour location and PD-1 and PD-L1 expression, an interaction variable was constructed with tumour location (right/other, left/other, or rectal/other, respectively) x immune cell-specific PD-1 or PD-L1 expression, or tumour cell-specific PD-L1 expression, respectively (low/high).
All calculations were performed using SPSS version 24.0 (SPSS Inc, Chicago, IL). All statistical tests were two-sided and p-values < 0.05 were considered statistically significant.
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